United States Hematologic Malignancy Therapeutics Market 2025: Market Size to hit US$ 154.32 billion by 2033

global hematologic malignancy therapeutics market reached US$ 71.80 billion in 2023, with a rise to US$ 77.06 billion in 2024, and is expected to reach US$ 154.32 billion by 2033, growing at a CAGR of 8.0% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/hematologic-malignancy-therapeutics-market?kb

Key Market Highlights From This Report

✅ North America captured about 42.5% of the hematologic malignancy therapeutics market in 2024, retaining leadership due to advanced healthcare systems, supportive regulations, and strong uptake of targeted and immuno-oncology treatments.

✅ Asia-Pacific held around 18.7% in 2024 and is poised to grow the fastest, fueled by rising blood cancer incidence, improved healthcare access, government support, increasing awareness, and expanding clinical research activity.

✅ Chemotherapy remained the leading treatment segment in 2024 with 42.5% revenue share, maintaining dominance as the long-established standard of care for leukemia, lymphoma, and multiple myeloma.

Key Players:

Pfizer Inc., F. Hoffmann-La Roche Ltd, Sanofi, Syndax Pharmaceuticals, Novartis Pharmaceuticals Corporation, GSK plc, Johnson & Johnson, Amgen Inc., AbbVie

Key industry Development:

In February 2025, Pfizer Inc. received U.S. FDA approval for a supplemental Biologics License Application (sBLA) for ADCETRIS (brentuximab vedotin) in combination with lenalidomide and rituximab to treat adult patients with relapsed or refractory large B-cell lymphoma (LBCL) - including DLBCL and high-grade B-cell lymphoma (HGBL) - after two or more prior therapies, who are not eligible for stem cell transplantation or CAR T-cell therapy.

In September 2025, Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced that the Journal of Clinical Oncology published the full pivotal KOMET-001 trial results (NCT04067336) evaluating ziftomenib, an investigational oral menin inhibitor, in adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML).

Growth Forecast Projection:

The Global Hematologic Malignancy Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Hematologic Malignancy Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=hematologic-malignancy-therapeutics-market?kb

Key Segmentation:

By Disease Condition: (Leukemia, Lymphoma, Multiple Myeloma)

By Therapy: (Chemotherapy, Immunotherapy, Targeted Therapy, Stem Cell Transplantation, Radiotherapy, Others),

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Latest M&A (oncology/hematology focus)

Johnson & Johnson agreed to acquire Halda Therapeutics for about $3.05 billion, adding its RIPTAC "hold-and-kill" targeted cancer platform, which includes programs relevant to blood cancers in an expanded oncology portfolio.​

Broader oncology M&A momentum (Pfizer /Seagen, Merck /Cidara Therapeutics, Novartis /Avidity Biosciences) continues to indirectly support hematologic malignancy pipelines via antibody-drug conjugates and RNA-targeted agents that also have heme-onc applications.

Latest Investments / Market Outlook

The global hematologic malignancy therapeutics market is projected to grow robustly, driven by rising prevalence of leukemia, lymphoma, and myeloma, growing adoption of targeted therapies (BTK, BCL‐2, CD38, BCMA) and cell and gene therapies (CAR‐T, bispecifics).​

In the U.S., hematologic malignancies treatment market is expected to see strong revenue growth through 2030 as newer targeted and cellular therapies gain reimbursement and move earlier in lines of therapy.​

Japan's market growth is supported by national cancer strategies, rapid uptake of novel myeloma regimens, and increased participation in multinational heme-onc trials across university hospitals

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/hematologic-malignancy-therapeutics-market?kb

Latest Drugs and Product / Label Updates (USA/Japan)

⇥ The FDA granted traditional approval to Darzalex Faspro (daratumumab and hyaluronidase-fihj) for AL amyloidosis in combination with bortezomib, cyclophosphamide, and dexamethasone, solidifying long‐term use of CD38-targeted therapy in hematologic disorders beyond multiple myeloma.​

⇥ FDA updated hematologic malignancy approvals including tafasitamab-cxix (Monjuvi) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma, expanding options in indolent lymphomas.​

⇥ In Japan, real‐world data confirmed safety and efficacy of subcutaneous Ig20Gly in patients with hematologic malignancies and secondary immunodeficiency, supporting its use in infection prophylaxis and supportive care for blood cancer patients

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/hematologic-malignancy-therapeutics-market?kb

Latest Clinical Trials (USA and Japan)

✅ A first‐in‐human trial of DS3790a (NCT07220616), a Daiichi Sankyo oral agent, is underway in hematologic malignancies; primary objective is safety with early signals suggesting potential activity across multiple heme indications.​

✅ The Asian Myeloma Network continues to run region‐wide trials that include Japan for frontline and relapsed myeloma combinations (e.g., daratumumab- and isatuximab-based regimens), allowing earlier access to innovative therapies for Japanese patients.​

✅ NIH‐reported advances include novel bispecific antibodies, next‐generation BTK inhibitors, and combination regimens for AML, CLL, and lymphomas in active U.S. trials, supporting a strong innovation pipeline.​

Key Project / Research Hubs

✦ USA: Major hematologic malignancy centers include MD Anderson, Dana‐Farber, Memorial Sloan Kettering, and Mayo Clinic, which lead many CAR‐T, bispecific, and targeted therapy trials and are key sites for global phase 2/3 studies.​

✦ Japan: Leading hubs include large university hospitals in Tokyo, Osaka, Nagoya, and AMN sites participating in multinational myeloma and lymphoma trials, plus institutions generating real‐world evidence in Ig20Gly and other supportive therapies.

✦ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.